OAB-003: CARDAMON:Carfilzomib (K) maintenance following Autologous Stem Cell Transplant (ASCT) or carfilzomib-cyclophosphamide-dexamethasone (KCd) consolidation for newly diagnosed (NDTE) multiple myeloma (MM)
Rakesh Popat(University College London Hospitals NHS Foundation Trust), Kwee Yong(CRUK Lung Cancer Centre of Excellence), Jonathan Sive(University College London Hospitals NHS Foundation Trust), Elizabeth H. Phillips(University of Manchester), James D. Cavenagh(National Health Service), Tushhar Dadaga(Cancer Research UK), Laura Clifton‐Hadley(Cancer Research UK), Ceri Bygrave(Cardiff and Vale University Health Board), Matthew Streetly(King's College - North Carolina), Gavin Pang(Cancer Research UK), Roger G. Owen(Leeds Teaching Hospitals NHS Trust), Lydia Eccersley(Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo), Karthik Ramasamy(Oxford University Hospitals NHS Trust), Richard G. Jenner(Cancer Research UK), M.D. Chapman, Ruth de Tute(Leeds Teaching Hospitals NHS Trust), Marquita Camilleri(University College London Hospitals NHS Foundation Trust), Sumaiya Kamora(Cancer Research UK), Sandra Hassan(Queen's Hospital), Reuben Benjamin(King's College London), Fenella Willis(St George's Hospital), William Wilson(Cancer Research UK)
Cited by 1
Related Papers
High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
|New England Journal of Medicine|2003|1.8k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
|Blood|2015|1.2k
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719
Monoclonal B-Cell Lymphocytosis and Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2008|605